SCHEMBL1333336

SCHEMBL1333336

N#Cc1cc(Oc2cccc(F)c2)ccc1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.43
AR P10275 5/20 0.43
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
PGGT1B P53609 1/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
GAA P10253 2/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
MITF O75030 1/20 0.41
GFER P55789 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NLRP1 Q9C000 1/20 0.41
NOD2 Q9HC29 1/20 0.41
NR4A1 P22736 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
GCK P35557 1/20 0.40
SLC22A12 Q96S37 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1335503 0.87 NR4A1 (0.42) CYP19A1ARNR4A1CNR1CNR2
SCHEMBL5073657 0.85 NR4A1 (0.54) CYP19A1ARMEN1ALDH1A1GAA
SCHEMBL9746279 0.84 CYP19A1 (0.56) CYP19A1ARFNTAFNTBPGGT1B
SCHEMBL9746052 0.84 CYP19A1 (0.56) CYP19A1ARFNTAFNTBPGGT1B
SCHEMBL1335043 0.83 ALDH1A1 (0.49) CYP19A1ARMEN1ALDH1A1GAA
SCHEMBL1334294 0.83 ALDH1A1 (0.49) CYP19A1ARMEN1ALDH1A1GAA
SCHEMBL11481973 0.83 NR4A1 (0.52) CYP19A1ARMEN1ALDH1A1GAA
SCHEMBL12260812 0.83 CYP19A1 (0.44) CYP19A1ARFNTAFNTBPGGT1B
SCHEMBL177542 0.79 AR (0.44) CYP19A1ARFNTAFNTBPGGT1B
SCHEMBL1336477 0.79 MAOB (0.61)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373626-B1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-08-24 EP disclosed
US-8354399-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-01-15 US disclosed
US-20110281843-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-11-17 US disclosed
EP-2373626-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP disclosed
WO-2010069966-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281843-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, MAP3K3, MAP3K5 CYP19A1 1078/4885AR 1458/4885FNTA 2286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.